Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types.

Autor: Silva MA; Department of Translational Medicine and Clinical Pharmacology, Boehringer-Ingelheim GmbH, Ingelheim am Rhein, Hesse, Germany., Williams S; Hematogenix, Chicago, Illinois, United States of America., Hauert S; Hematogenix, Chicago, Illinois, United States of America., Ovadia B; NeoGenomics, Fort Myers, Florida, United States of America., Gupta I; NeoGenomics, Fort Myers, Florida, United States of America., Waldmeier L; NBE Therapeutics AG, Basel, Switzerland., Jaimes Y; Department of Translational Medicine and Clinical Pharmacology, Boehringer-Ingelheim GmbH, Ingelheim am Rhein, Hesse, Germany., Al-Masri H; Hematogenix, Chicago, Illinois, United States of America.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2024 Nov 04; Vol. 19 (11), pp. e0313026. Date of Electronic Publication: 2024 Nov 04 (Print Publication: 2024).
DOI: 10.1371/journal.pone.0313026
Abstrakt: Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a tumour target currently used for the development of novel therapeutic modalities, such as antibody-drug conjugates, chimeric antigen receptor T-cell therapies, and others. Success of these new drugs depends on the selection of relevant indications based on ROR1 tumour prevalence, staining heterogeneity, and subcellular localization, among other parameters. We investigated ROR1 immunophenotype using validated antibody clones for immunohistochemistry (IHC) and flow cytometry (FC), analyzing 292 tumour specimens from 7 haematological malignancies and triple negative breast cancer (TNBC) as a reference solid tumour indication. ROR1 prevalence varied significantly across distinct tumour types, showing 100% of ROR1 positivity in all chronic lymphocytic leukaemia (n = 48) and hairy cell leukaemia (n = 14) specimens analyzed via FC with ranges between 1.1-99.8% and 0.8-62.1%, respectively. Samples analysed via IHC showed ROR1 membrane/cytoplasmic positivity in 44% of mantle cell lymphoma tumour samples (n = 27; H-score range: 10-285 in positive cases); 30% in TNBC (n = 46; H-score range: 1-200); 15% in diffuse large B-cell lymphoma (n = 45; H-score: 40-250); and 11% in follicular lymphoma (n = 34; H-score: 2-300). Finally, all acute myeloid leukaemia (n = 52) and most T-cell non-Hodgkin lymphoma (n = 31/32) tested samples were negative for ROR1 via IHC. In conclusion, ROR1 shows a heterogeneous tumour cell expression profile across multiple leukaemias and lymphomas, making it a tumour target that would require different patient selection strategies to develop novel therapeutic modalities.
Competing Interests: This work was funded by Boehringer-Ingelheim GmbH, the employer of Manuel A. Silva, Lorenz Waldmeier and Yarúa Jaimes. Shuntae Williams, Sylvie Hauert, and Hytham Al-Masri are employed by Hematogenix. Benjamin Ovadia and Indu Gupta are employed by NeoGenomics. There are no patents, products in development or marketed products to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
(Copyright: © 2024 Silva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje